{"transactions":[{"id":1172889,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-14T23:14:36.000Z","date":"2025-04-10","kind":"sale","planned":false,"acquired":false,"shares":17109618,"price":0.42,"value":7186039.56,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Royalty Opportunities II, LP (\"ORO II\"). OrbiMed ROF II LLC (\"ROF II\") is the general partner of ORO II, and OrbiMed Advisors is the managing member of ROF II. By virtue of such relationships, ROF II and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by ORO II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and ROF II. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-25-000392","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000392/ownership.xml","form_type":"4"}},{"id":1172888,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-14T23:14:36.000Z","date":"2025-04-10","kind":"sale","planned":false,"acquired":false,"shares":56004974,"price":0.42,"value":23522089.08,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by ROS Acquisition Offshore LP (\"ROS Acquisition\"). OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. By virtue of such relationships, OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and ROF II. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-25-000392","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000392/ownership.xml","form_type":"4"}},{"id":2182403,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.000001 par value","published_at":"2022-08-17T20:31:24.000Z","date":"2022-08-15","kind":"other","acquired":true,"shares":215415,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"This restricted stock unit award was granted to Rizzo, a director of Xtant."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 23, 2023, conditioned upon each of Eggenberg and Matthew Rizzo (\"Rizzo\") remaining a director of Xtant through the vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 23, 2023, conditioned upon each of Eggenberg and Matthew Rizzo (\"Rizzo\") remaining a director of Xtant through the vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"See Exhibit 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and ROF II. Each of OrbiMed Advisors and ROF II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated certain representatives, including Rizzo and Eggenberg, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":215415,"source":{"system":"sec-edgar","filing":"0001235802-22-000096","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580222000096/primary_doc.xml","form_type":"4"}},{"id":2182402,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.000001 par value","published_at":"2022-08-17T20:31:24.000Z","date":"2022-08-15","kind":"other","acquired":true,"shares":215415,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This restricted stock unit award was granted to Michael Eggenberg (\"Eggenberg\"), a director of Xtant Medical Holdings, Inc. (\"Xtant\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 23, 2023, conditioned upon each of Eggenberg and Matthew Rizzo (\"Rizzo\") remaining a director of Xtant through the vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, and vest and become issuable on August 23, 2023, conditioned upon each of Eggenberg and Matthew Rizzo (\"Rizzo\") remaining a director of Xtant through the vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"See Exhibit 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and ROF II. Each of OrbiMed Advisors and ROF II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated certain representatives, including Rizzo and Eggenberg, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":215415,"source":{"system":"sec-edgar","filing":"0001235802-22-000096","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580222000096/primary_doc.xml","form_type":"4"}},{"id":2600836,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-17T21:58:37.000Z","date":"2021-08-15","kind":"other","acquired":true,"shares":85337,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"See Exhibit 99.2."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by Advisors and ROF II.  Each of ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"See Exhibit 99.2."}],"balance_after":120549,"source":{"system":"sec-edgar","filing":"0001235802-21-000109","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580221000109/primary_doc.xml","form_type":"4"}},{"id":2600835,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-17T21:58:37.000Z","date":"2021-08-15","kind":"other","acquired":true,"shares":85337,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"See Exhibit 99.1."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and vest and become issuable on August 15, 2022, conditioned upon the reporting person remaining a director of Xtant through the vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by Advisors and ROF II.  Each of ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":120549,"source":{"system":"sec-edgar","filing":"0001235802-21-000109","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580221000109/primary_doc.xml","form_type":"4"}},{"id":2628486,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-21T21:30:13.000Z","date":"2021-07-19","kind":"purchase","acquired":true,"shares":357143,"price":14,"value":5000002.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Royalty Opportunities II, LP (\"ORO II\"). OrbiMed ROF II LLC (\"ROF II\") is the general partner of ORO II, and OrbiMed Advisors is the managing member of ORO II. OrbiMed Advisors and ROF II exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by ORO II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by GP IV, ROF II, and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP IV have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":1677361,"source":{"system":"sec-edgar","filing":"0000947871-21-000788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000788/ownership.xml","form_type":"4"}},{"id":2628485,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-21T21:30:13.000Z","date":"2021-07-19","kind":"purchase","acquired":true,"shares":714285,"price":14,"value":9999990.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments IV, LP (\"OPI IV\"). OrbiMed Capital GP IV LLC (\"GP IV\") is the general partner of OPI IV, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP IV. OrbiMed Advisors and GP IV exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by GP IV, ROF II, and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP IV have designated David Bonita (\"Bonita\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":4872025,"source":{"system":"sec-edgar","filing":"0000947871-21-000788","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000788/ownership.xml","form_type":"4"}},{"id":2973522,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2020-11-19T23:02:18.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":868016,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by ORO II. ROF II is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II."}],"balance_after":0,"derivative":{"exercise_price":0.01,"exercise_date":"2020-11-06","expiration_date":"2030-05-06","underlying":"Common Stock","underlying_shares":868016},"source":{"system":"sec-edgar","filing":"0001235802-20-000137","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000137/primary_doc.xml","form_type":"4"}},{"id":2973521,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2020-11-19T23:02:18.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":1531984,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by ROS Acquisition Offshore LP (\"ROS Acquisition\"). OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition.  Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary.  By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities.  Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":0.01,"exercise_date":"2020-11-06","expiration_date":"2030-05-06","underlying":"Common Stock","underlying_shares":1531984},"source":{"system":"sec-edgar","filing":"0001235802-20-000137","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000137/primary_doc.xml","form_type":"4"}},{"id":2973520,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2020-11-19T23:02:18.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":434008,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by ORO II. ROF II is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II."}],"balance_after":0,"derivative":{"exercise_price":0.01,"exercise_date":"2019-04-11","expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":434008},"source":{"system":"sec-edgar","filing":"0001235802-20-000137","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000137/primary_doc.xml","form_type":"4"}},{"id":2973519,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2020-11-19T23:02:18.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":765992,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by ROS Acquisition Offshore LP (\"ROS Acquisition\"). OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition.  Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary.  By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities.  Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":0.01,"exercise_date":"2019-04-11","expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":765992},"source":{"system":"sec-edgar","filing":"0001235802-20-000137","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000137/primary_doc.xml","form_type":"4"}},{"id":2973518,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2020-11-19T23:02:18.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":434008,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by ORO II. ROF II is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II."}],"balance_after":0,"derivative":{"exercise_price":0.01,"exercise_date":"2018-09-17","expiration_date":"2028-08-01","underlying":"Common Stock","underlying_shares":434008},"source":{"system":"sec-edgar","filing":"0001235802-20-000137","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000137/primary_doc.xml","form_type":"4"}},{"id":2973517,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2020-11-19T23:02:18.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":765992,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by ROS Acquisition Offshore LP (\"ROS Acquisition\"). OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition.  Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary.  By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities.  Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":0,"derivative":{"exercise_price":0.01,"exercise_date":"2018-09-17","expiration_date":"2028-08-01","underlying":"Common Stock","underlying_shares":765992},"source":{"system":"sec-edgar","filing":"0001235802-20-000137","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000137/primary_doc.xml","form_type":"4"}},{"id":2973516,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T23:02:18.000Z","date":"2020-11-17","kind":"other","acquired":true,"shares":868016,"price":0.01,"value":8680.16,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by ORO II. ROF II is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II."}],"balance_after":17036720,"source":{"system":"sec-edgar","filing":"0001235802-20-000137","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000137/primary_doc.xml","form_type":"4"}},{"id":2973515,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T23:02:18.000Z","date":"2020-11-17","kind":"other","acquired":true,"shares":434008,"price":0.01,"value":4340.08,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by ORO II. ROF II is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II."}],"balance_after":16168704,"source":{"system":"sec-edgar","filing":"0001235802-20-000137","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000137/primary_doc.xml","form_type":"4"}},{"id":2973514,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T23:02:18.000Z","date":"2020-11-17","kind":"other","acquired":true,"shares":434008,"price":0.01,"value":4340.08,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by ORO II. ROF II is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II."}],"balance_after":15734696,"source":{"system":"sec-edgar","filing":"0001235802-20-000137","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000137/primary_doc.xml","form_type":"4"}},{"id":2973513,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T23:02:18.000Z","date":"2020-11-17","kind":"other","acquired":true,"shares":1531984,"price":0.01,"value":15319.84,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by ROS Acquisition Offshore LP (\"ROS Acquisition\"). OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition.  Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary.  By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities.  Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":55766352,"source":{"system":"sec-edgar","filing":"0001235802-20-000137","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000137/primary_doc.xml","form_type":"4"}},{"id":2973512,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T23:02:18.000Z","date":"2020-11-17","kind":"other","acquired":true,"shares":765992,"price":0.01,"value":7659.92,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by ROS Acquisition Offshore LP (\"ROS Acquisition\"). OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition.  Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary.  By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities.  Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":54234368,"source":{"system":"sec-edgar","filing":"0001235802-20-000137","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000137/primary_doc.xml","form_type":"4"}},{"id":2973511,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T23:02:18.000Z","date":"2020-11-17","kind":"other","acquired":true,"shares":765992,"price":0.01,"value":7659.92,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by ROS Acquisition Offshore LP (\"ROS Acquisition\"). OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition.  Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary.  By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities.  Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":53468376,"source":{"system":"sec-edgar","filing":"0001235802-20-000137","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000137/primary_doc.xml","form_type":"4"}},{"id":3013881,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-05T20:14:21.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":11969619,"price":1.07,"value":12807492.33,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"See Exhibit 99.1"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by ORO II. ROF II is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II."}],"balance_after":15300688,"source":{"system":"sec-edgar","filing":"0001235802-20-000117","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000117/primary_doc.xml","form_type":"4"}},{"id":3013880,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-05T20:14:21.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":46784775,"price":1.07,"value":50059709.25,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"See Exhibit 99.1"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"See Exhibit 99.1"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by ROS Acquisition. OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition.  Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary.  By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities.  Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of Advisors, ROF II, ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any.  Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":52702384,"source":{"system":"sec-edgar","filing":"0001235802-20-000117","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000117/primary_doc.xml","form_type":"4"}},{"id":3060668,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2020-08-13T01:06:09.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":378733,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Royalty Opportunities II, LP (\"ORO II\"). OrbiMed ROF II LLC (\"ROF II\") is the general partner of ORO II. OrbiMed Advisors is the managing member of ROF II. By virtue of such relationships, ROF II and\nOrbiMed Advisors may be deemed to have voting and investment power over the securities held by ORO II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a\nmanagement committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by ORO II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":378733},"source":{"system":"sec-edgar","filing":"0000950103-20-015724","document":"dp134361_4-orbimed.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095010320015724/dp134361_4-orbimed.xml","form_type":"4"}},{"id":3060667,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2020-08-13T01:06:09.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":1202117,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments IV, LP (\"OPI IV\"). OrbiMed Capital GP IV LLC (\"GP IV\") is the general partner of OPI IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1202117},"source":{"system":"sec-edgar","filing":"0000950103-20-015724","document":"dp134361_4-orbimed.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095010320015724/dp134361_4-orbimed.xml","form_type":"4"}},{"id":3060666,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2020-08-13T01:06:09.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":389116,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments IV, LP (\"OPI IV\"). OrbiMed Capital GP IV LLC (\"GP IV\") is the general partner of OPI IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":389116},"source":{"system":"sec-edgar","filing":"0000950103-20-015724","document":"dp134361_4-orbimed.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095010320015724/dp134361_4-orbimed.xml","form_type":"4"}},{"id":3060665,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-08-13T01:06:09.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":899985,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Royalty Opportunities II, LP (\"ORO II\"). OrbiMed ROF II LLC (\"ROF II\") is the general partner of ORO II. OrbiMed Advisors is the managing member of ROF II. By virtue of such relationships, ROF II and\nOrbiMed Advisors may be deemed to have voting and investment power over the securities held by ORO II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a\nmanagement committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by ORO II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":899985},"source":{"system":"sec-edgar","filing":"0000950103-20-015724","document":"dp134361_4-orbimed.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095010320015724/dp134361_4-orbimed.xml","form_type":"4"}},{"id":3060664,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2020-08-13T01:06:09.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":647582,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments IV, LP (\"OPI IV\"). OrbiMed Capital GP IV LLC (\"GP IV\") is the general partner of OPI IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":647582},"source":{"system":"sec-edgar","filing":"0000950103-20-015724","document":"dp134361_4-orbimed.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095010320015724/dp134361_4-orbimed.xml","form_type":"4"}},{"id":3060663,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-08-13T01:06:09.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":673123,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments IV, LP (\"OPI IV\"). OrbiMed Capital GP IV LLC (\"GP IV\") is the general partner of OPI IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":673123},"source":{"system":"sec-edgar","filing":"0000950103-20-015724","document":"dp134361_4-orbimed.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095010320015724/dp134361_4-orbimed.xml","form_type":"4"}},{"id":3060662,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-08-13T01:06:09.000Z","date":"2020-08-10","kind":"exercise","acquired":false,"shares":872302,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each of the Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, and Series D Convertible Preferred Stock is convertible into the Issuer's Common Stock on a one-for-one basis for no additional consideration and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments IV, LP (\"OPI IV\"). OrbiMed Capital GP IV LLC (\"GP IV\") is the general partner of OPI IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":872302},"source":{"system":"sec-edgar","filing":"0000950103-20-015724","document":"dp134361_4-orbimed.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095010320015724/dp134361_4-orbimed.xml","form_type":"4"}},{"id":3060661,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-13T01:06:09.000Z","date":"2020-08-10","kind":"exercise","acquired":true,"shares":1278718,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Royalty Opportunities II, LP (\"ORO II\"). OrbiMed ROF II LLC (\"ROF II\") is the general partner of ORO II. OrbiMed Advisors is the managing member of ROF II. By virtue of such relationships, ROF II and\nOrbiMed Advisors may be deemed to have voting and investment power over the securities held by ORO II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a\nmanagement committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by ORO II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":1320218,"source":{"system":"sec-edgar","filing":"0000950103-20-015724","document":"dp134361_4-orbimed.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095010320015724/dp134361_4-orbimed.xml","form_type":"4"}},{"id":3060660,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-13T01:06:09.000Z","date":"2020-08-10","kind":"exercise","acquired":true,"shares":3784240,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments IV, LP (\"OPI IV\"). OrbiMed Capital GP IV LLC (\"GP IV\") is the general partner of OPI IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":4157740,"source":{"system":"sec-edgar","filing":"0000950103-20-015724","document":"dp134361_4-orbimed.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095010320015724/dp134361_4-orbimed.xml","form_type":"4"}},{"id":3060659,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-13T01:06:09.000Z","date":"2020-08-10","kind":"purchase","acquired":true,"shares":41500,"price":18,"value":747000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Royalty Opportunities II, LP (\"ORO II\"). OrbiMed ROF II LLC (\"ROF II\") is the general partner of ORO II. OrbiMed Advisors is the managing member of ROF II. By virtue of such relationships, ROF II and\nOrbiMed Advisors may be deemed to have voting and investment power over the securities held by ORO II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a\nmanagement committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by ORO II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":41500,"source":{"system":"sec-edgar","filing":"0000950103-20-015724","document":"dp134361_4-orbimed.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095010320015724/dp134361_4-orbimed.xml","form_type":"4"}},{"id":3060658,"issuer":{"id":83848,"kind":"organization","name":"Acutus Medical, Inc.","symbol":"AFIB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89303,"kind":"organization","name":"OrbiMed Capital GP IV LLC","position":2,"cik":"0001502240","reported_name":"OrbiMed Capital GP IV LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":3,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-13T01:06:09.000Z","date":"2020-08-10","kind":"purchase","acquired":true,"shares":373500,"price":18,"value":6723000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments IV, LP (\"OPI IV\"). OrbiMed Capital GP IV LLC (\"GP IV\") is the general partner of OPI IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IV. By virtue of such relationships, GP IV and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of GP IV, ROF II, and OrbiMed Advisors disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated a representative, currently David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors."}],"balance_after":373500,"source":{"system":"sec-edgar","filing":"0000950103-20-015724","document":"dp134361_4-orbimed.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095010320015724/dp134361_4-orbimed.xml","form_type":"4"}},{"id":3141251,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2020-05-20T21:27:56.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":868016,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This warrant was issued by Xtant Medical Holdings, Inc. in connection with that certain First Amendment to Second Amended and Restated Credit Agreement, effective as of April 1, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Only represents derivative securities of this class."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by ORO II.  ROF II is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II."}],"balance_after":868016,"derivative":{"exercise_price":0.01,"exercise_date":"2020-11-06","expiration_date":"2030-05-06","underlying":"Common Stock","underlying_shares":868016},"source":{"system":"sec-edgar","filing":"0001235802-20-000048","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000048/primary_doc.xml","form_type":"4"}},{"id":3141250,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2020-05-20T21:27:56.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":1531984,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This warrant was issued by Xtant Medical Holdings, Inc. in connection with that certain First Amendment to Second Amended and Restated Credit Agreement, effective as of April 1, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Only represents derivative securities of this class."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by ROS Acquisition Offshore LP (\"ROS Acquisition\"). OrbiMed Advisors LLC (\"Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC (\"ROF II\"). Each of ROS Acquisition and OrbiMed Royalty Opportunities II, LP (\"ORO II\") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":1531984,"derivative":{"exercise_price":0.01,"exercise_date":"2020-11-06","expiration_date":"2030-05-06","underlying":"Common Stock","underlying_shares":1531984},"source":{"system":"sec-edgar","filing":"0001235802-20-000048","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000048/primary_doc.xml","form_type":"4"}},{"id":3284969,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.000001 par value","published_at":"2020-02-07T22:05:21.000Z","date":"2020-02-05","kind":"other","acquired":true,"shares":70423,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"See Exhibit 99.2."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 35,211 shares on February 15, 2021 and with respect to 35,212 shares on February 15, 2022, conditioned upon Michael Eggenberg and Matthew Rizzo, respectively, remaining directors of Xtant through the vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by Advisors and ROF II.  Each of ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"See Exhibit 99.2."}],"balance_after":91256,"source":{"system":"sec-edgar","filing":"0001235802-20-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000008/primary_doc.xml","form_type":"4"}},{"id":3284968,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.000001 par value","published_at":"2020-02-07T22:05:21.000Z","date":"2020-02-05","kind":"other","acquired":true,"shares":70423,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"See Exhibit 99.1."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended, and will vest and become issuable with respect 35,211 shares on February 15, 2021 and with respect to 35,212 shares on February 15, 2022, conditioned upon Michael Eggenberg and Matthew Rizzo, respectively, remaining directors of Xtant through the vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by Advisors and ROF II.  Each of ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":91256,"source":{"system":"sec-edgar","filing":"0001235802-20-000008","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000123580220000008/primary_doc.xml","form_type":"4"}},{"id":3384745,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.000001 par value","published_at":"2019-10-31T21:17:43.000Z","date":"2019-10-30","kind":"other","acquired":true,"shares":20833,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"See Exhibit 99.2."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and will vest and become issuable on February 15, 2020, conditioned upon Michael Eggenberg and Matthew Rizzo, respectively, remaining directors of Xtant through the vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by Advisors and ROF II.  Each of ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"See Exhibit 99.2."}],"balance_after":20833,"source":{"system":"sec-edgar","filing":"0001790300-19-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000179030019000006/primary_doc.xml","form_type":"4"}},{"id":3384744,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.000001 par value","published_at":"2019-10-31T21:17:43.000Z","date":"2019-10-30","kind":"other","acquired":true,"shares":20833,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"See Exhibit 99.1."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are subject to restricted stock unit awards granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and will vest and become issuable on February 15, 2020, conditioned upon Michael Eggenberg and Matthew Rizzo, respectively, remaining directors of Xtant through the vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"See Exhibit 99.1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by Advisors and ROF II.  Each of ROS Acquisition and ORO II disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on Xtant's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes."}],"balance_after":20833,"source":{"system":"sec-edgar","filing":"0001790300-19-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000179030019000006/primary_doc.xml","form_type":"4"}},{"id":3565938,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2019-04-03T17:06:13.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":434008,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This warrant was acquired from Xtant Medical Holdings, Inc. in connection with and as a condition to the effectiveness of that certain Second Amended and Restated Credit Agreement, effective as of March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Royalty Opportunities II, LP (\"ORO II\"). OrbiMed ROF II LLC (\"ROF II\") is the sole general partner of ORO II, and Advisors is the sole managing member of ROF II. By virtue of such relationships, ROF II and Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by Advisors and ROF II. Each of ROS Acquisition, ORO II and the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The reporting persons have designated two representatives, currently Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or the reporting person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":434008,"derivative":{"exercise_price":0.01,"exercise_date":"2019-04-01","expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":434008},"source":{"system":"sec-edgar","filing":"0000947871-19-000265","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000265/ownership.xml","form_type":"4"}},{"id":3565937,"issuer":{"id":7196,"kind":"organization","name":"Xtant Medical Holdings, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2019-04-03T17:06:13.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":765992,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This warrant was acquired from Xtant Medical Holdings, Inc. in connection with and as a condition to the effectiveness of that certain Second Amended and Restated Credit Agreement, effective as of March 29, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by ROS Acquisition Offshore LP (\"ROS Acquisition\"). OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by Advisors and ROF II. Each of ROS Acquisition, ORO II and the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The reporting persons have designated two representatives, currently Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or the reporting person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":765992,"derivative":{"exercise_price":0.01,"exercise_date":"2019-04-01","expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":765992},"source":{"system":"sec-edgar","filing":"0000947871-19-000265","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787119000265/ownership.xml","form_type":"4"}},{"id":3650736,"issuer":{"id":153528,"kind":"organization","name":"AVEDRO INC","symbol":"AVDR"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series CC Convertible Preferred Stock","published_at":"2019-02-20T00:14:31.000Z","date":"2019-02-19","kind":"exercise","acquired":false,"shares":383746,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OPI VI, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP VI, OrbiMed ROF II LLC (\"ROF II\") and Advisors. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. GP VI and Advisors have designated a representative, Jonathan T. Silverstein, a member of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":383746},"source":{"system":"sec-edgar","filing":"0001209191-19-011336","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919119011336/doc4.xml","form_type":"4"}},{"id":3650735,"issuer":{"id":153528,"kind":"organization","name":"AVEDRO INC","symbol":"AVDR"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series BB Convertible Preferred Stock","published_at":"2019-02-20T00:14:31.000Z","date":"2019-02-19","kind":"exercise","acquired":false,"shares":333178,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OPI VI, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP VI, OrbiMed ROF II LLC (\"ROF II\") and Advisors. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. GP VI and Advisors have designated a representative, Jonathan T. Silverstein, a member of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":333178},"source":{"system":"sec-edgar","filing":"0001209191-19-011336","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919119011336/doc4.xml","form_type":"4"}},{"id":3650734,"issuer":{"id":153528,"kind":"organization","name":"AVEDRO INC","symbol":"AVDR"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series AA Convertible Preferred Stock","published_at":"2019-02-20T00:14:31.000Z","date":"2019-02-19","kind":"exercise","acquired":false,"shares":3370786,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OPI VI, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP VI, OrbiMed ROF II LLC (\"ROF II\") and Advisors. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. GP VI and Advisors have designated a representative, Jonathan T. Silverstein, a member of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3370786},"source":{"system":"sec-edgar","filing":"0001209191-19-011336","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919119011336/doc4.xml","form_type":"4"}},{"id":3650733,"issuer":{"id":153528,"kind":"organization","name":"AVEDRO INC","symbol":"AVDR"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-20T00:14:31.000Z","date":"2019-02-19","kind":"exercise","acquired":true,"shares":383746,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OPI VI, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP VI, OrbiMed ROF II LLC (\"ROF II\") and Advisors. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. GP VI and Advisors have designated a representative, Jonathan T. Silverstein, a member of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":4240128,"source":{"system":"sec-edgar","filing":"0001209191-19-011336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919119011336/doc4.xml","form_type":"4"}},{"id":3650732,"issuer":{"id":153528,"kind":"organization","name":"AVEDRO INC","symbol":"AVDR"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-20T00:14:31.000Z","date":"2019-02-19","kind":"exercise","acquired":true,"shares":333178,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OPI VI, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP VI, OrbiMed ROF II LLC (\"ROF II\") and Advisors. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. GP VI and Advisors have designated a representative, Jonathan T. Silverstein, a member of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3856382,"source":{"system":"sec-edgar","filing":"0001209191-19-011336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919119011336/doc4.xml","form_type":"4"}},{"id":3650731,"issuer":{"id":153528,"kind":"organization","name":"AVEDRO INC","symbol":"AVDR"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":80844,"kind":"organization","name":"Orbimed ROF II LLC","position":2,"cik":"0001767936","reported_name":"Orbimed ROF II LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-20T00:14:31.000Z","date":"2019-02-19","kind":"exercise","acquired":true,"shares":3370786,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series AA Convertible Preferred Stock, Series BB Convertible Preferred Stock and Series CC Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the sole general partner of OPI VI, and OrbiMed Advisors LLC (\"Advisors\"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by GP VI, OrbiMed ROF II LLC (\"ROF II\") and Advisors. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. GP VI and Advisors have designated a representative, Jonathan T. Silverstein, a member of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3523204,"source":{"system":"sec-edgar","filing":"0001209191-19-011336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000120919119011336/doc4.xml","form_type":"4"}}]}